



Fig A3. Estimated Kaplan-Meier progression-free survival (by independent review facility) curves by PD-L1 status for patients with advanced non-small-cell lung cancer treated with atezolizumab in the BIRCH trial. TC2 or IC2 patients were determined by excluding TC3 or IC3 patients from TC2/3 or IC2/3 patients. (A) Cohort 1 (1L), (B) cohort 2 (2L), and (C) cohort 3 (3L). On the basis of a data cutoff of December 1, 2015. 1L, first line; 2L, second line, 3L, third line; IC, tumor-infiltrating immune cells; PD-L1, programmed death-ligand 1; TC, tumor cells; TC2/3 or IC2/3 = TC or IC 5% PD-L1-expressing cells, respectively; TC3 or IC3 = TC 50% or IC 10% PD-L1-expressing cells, respectively.